Q-omics provides the consensus-scored GYG2P1 profile across patient tissues and cancer cell-line models. GYG2P1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GYG2P1 is differentially expressed in 8, with the highest sampling consensus in KIRP. Additionally, GYG2P1 RNA expression shows 7,688 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRP, and TGCT as cancer lineages where GYG2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GYG2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GYG2P1 survival associations across molecular data types. GYG2P1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GYG2P1 RNA expression–survival associations across cancer types. High GYG2P1 expression shows unfavorable associations in PAAD, LUSC, THCA and READ, but favorable associations in UVM and MESO. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GYG2P1 RNA expression.
This table summarizes GYG2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GYG2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GYG2P1 shows lower tumor expression in KIRP, KIRC, KICH and LUSC and higher tumor expression in THCA and STAD. The KIRP box plot shows higher GYG2P1 RNA expression in normal versus tumor tissue (log2 FC = −1.909, t-test p < 0.001).
This table shows molecular features associated with GYG2P1 in patient tissues and cancer cell lines. In patient samples, GYG2P1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
